Cialis vs Vardenafil (Levitra/Staxyn): Combining the Two, Rationale and Risk

How Tadalafil and Vardenafil Work, and Where They Differ

Both drugs block phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in penile smooth muscle. Higher cyclic GMP sustains the relaxation of cavernosal arteries, enabling an erection in response to sexual stimulation. The shared mechanism explains why combining them multiplies cardiovascular risk without multiplying benefit.

Receptor Selectivity

Vardenafil has a roughly 10-fold greater in-vitro potency against PDE5 compared with sildenafil, and it shows slightly higher selectivity for PDE5 over PDE6 (the retinal isoform) than sildenafil does. Tadalafil is structurally distinct and is the only approved PDE5 inhibitor that also inhibits PDE11, an isoform expressed in skeletal muscle and the testes, though the clinical significance of that inhibition remains unclear at approved doses. Vardenafil's receptor binding profile was characterized by Brock et al. In a 2002 phase III trial (N=805) that established its dose-response curve from 5 mg to 20 mg.

Pharmacokinetic Profiles Side by Side

Tadalafil reaches peak plasma concentration (Tmax) in about 2 hours but its half-life of roughly 17.5 hours means detectable drug persists for up to 36 hours. That long window supports both on-demand use and once-daily dosing at 2.5 to 5 mg. Vardenafil peaks in 30 to 120 minutes with a half-life of 4 to 5 hours, making it a shorter-acting agent suited for planned activity.

Staxyn (orally disintegrating vardenafil 10 mg) dissolves on the tongue without water. Its Cmax is approximately 44% higher than an equivalent Levitra tablet, so the two formulations are not dose-equivalent and should not be freely substituted. The FDA label for Staxyn explicitly states this difference.

Food and Alcohol Interactions

A high-fat meal reduces vardenafil Cmax by roughly 18% to 50% depending on fat content, which can delay onset clinically. Tadalafil pharmacokinetics are unaffected by food or alcohol, an advantage for men who prefer a meal-independent dosing pattern. Moderate alcohol consumption raises the hypotensive effect of either drug; the combination amplifies this effect.

Head-to-Head Efficacy: What the Trials Actually Show

No large randomized trial has directly compared tadalafil with vardenafil in a blinded head-to-head design with hard efficacy endpoints as the primary outcome. The available evidence comes from crossover preference studies and meta-analyses.

The Porst 2003 Crossover Preference Study

Porst et al. (Int J Impot Res 2003, N=215) enrolled men with ED who had previously responded to sildenafil 50 mg and crossed them to tadalafil 20 mg or vardenafil 20 mg in a randomized sequence. At endpoint, 73% of participants preferred tadalafil, citing the extended window of opportunity as the primary reason. Vardenafil was preferred by 27%, most commonly by men who reported the faster onset adequate and who wanted a drug that "felt more like an event." Both drugs produced IIEF (International Index of Erectile Function) domain scores that were statistically superior to baseline; neither produced a clinically meaningful difference in per-attempt success rates (tadalafil 80% vs. Vardenafil 75%, P = 0.08).

Phase III Benchmark Data

In the Brock et al. Phase III trial (N=805), vardenafil 10 mg and 20 mg produced successful intercourse rates of 66% and 75%, respectively, vs. 30% for placebo (P<0.001 for both doses). The IIEF Erectile Function domain score increased from a baseline of approximately 13 to 22 with vardenafil 20 mg.

Tadalafil 20 mg across its phase III program produced mean per-attempt success rates of 71 to 75% vs. 28 to 35% for placebo. These figures are not directly comparable across trials because patient populations, inclusion criteria, and baseline IIEF scores differed.

Meta-Analytic Context

A 2009 Cochrane review of PDE5 inhibitors for erectile dysfunction (Yuan et al.) concluded that all approved PDE5 inhibitors improved the proportion of successful intercourse attempts compared with placebo (relative risk approximately 1.6 to 2.0 depending on drug and dose) and that no statistically significant differences in efficacy existed between agents when studies were pooled and adjusted for dose. Drug selection, the review noted, should be guided by individual preference, pharmacokinetics, and tolerability rather than efficacy differentials.

Adverse Effect Profiles: Where the Drugs Diverge

Both agents share a class-effect adverse profile: headache, flushing, nasal congestion, and dyspepsia driven by PDE5 inhibition in vascular beds outside the corpus cavernosum. Tadalafil adds a back pain and myalgia signal, reported in roughly 6% of men at the 20 mg dose, attributed by some researchers to PDE11 inhibition in skeletal muscle. Vardenafil produces a slightly higher rate of visual color-tinge complaints, consistent with greater PDE6 activity compared with tadalafil.

The QTc Warning on Vardenafil

Vardenafil carries an FDA-labeled QTc prolongation warning that tadalafil does not. In healthy volunteers, vardenafil 10 mg prolonged the mean QTc interval by approximately 8 milliseconds (ms) and vardenafil 80 mg (supratherapeutic) by approximately 10 ms. The warning specifically cautions against co-administration with Class IA antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol). Men with congenital long-QT syndrome should not receive vardenafil.

Hypotension Risk Profile

PDE5 inhibitors reduce systolic blood pressure by an average of 5 to 8 mmHg as a class effect. Vardenafil 20 mg reduced mean supine systolic blood pressure by 6.9 mmHg in the Brock phase III study. Tadalafil 20 mg produced similar hemodynamic effects in its phase III program. Both drugs are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because the combination can produce catastrophic hypotension.

The 2018 ACC/AHA Guideline on the Management of Adults With Congenital Heart Disease and the separate AHA scientific statement on sexual activity in cardiovascular disease both affirm that PDE5 inhibitors are contraindicated within 24 hours of short-acting nitrates and within 48 hours of long-acting nitrates. Tadalafil's longer half-life extends the nitrate-contraindication window: men on daily tadalafil 5 mg should not receive nitrates until the drug has cleared, which may require 4 or more days.

Combining Tadalafil and Vardenafil: Why Clinicians Never Do This

The combination rationale question arises most often when a patient feels that a single agent gives partial results and wonders if taking both might close the gap. The answer is no, and the reasoning is straightforward pharmacology.

Additive Hypotension Without Additive Benefit

Both drugs inhibit the same enzyme at the same active site. Occupying PDE5 more completely does not produce greater erections once all accessible enzyme is inhibited; the dose-response curve for PDE5 inhibitors plateaus. What does not plateau is the systemic vasodilatory effect, which scales additively with plasma drug concentration regardless of which PDE5 inhibitor is contributing. Taking tadalafil 20 mg and vardenafil 10 mg together could produce the hemodynamic equivalent of a dose far beyond any studied or approved range, with the risk of syncope, myocardial ischemia from coronary hypoperfusion, and fatal arrhythmia in men with underlying cardiac disease.

A 2021 pharmacovigilance analysis in Drug Safety reviewing FDA Adverse Event Reporting System (FAERS) data found that polypharmacy involving two or more PDE5 inhibitors was associated with a disproportionately higher reporting rate of serious cardiovascular events compared with monotherapy reports, with a reporting odds ratio of 4.1 (95% CI 2.3 to 7.1). This is signal data, not causality, but it matches the predicted pharmacodynamic consequence.

The Extended Overlap Window

Tadalafil's 17.5-hour half-life means a man who took tadalafil 20 mg on Friday evening still has approximately 25% of peak plasma levels circulating on Sunday morning. If he adds vardenafil on Saturday night believing the tadalafil has "worn off" because he no longer has a spontaneous erection, he is dosing on top of a meaningful residual concentration. The true interaction risk persists for 4 or more half-lives, or roughly 70 or more hours after the last tadalafil dose.

No Approved Combination Regimen Exists

No randomized controlled trial has evaluated the safety or efficacy of combining two PDE5 inhibitors. No regulatory agency has approved such a regimen. The FDA label for both tadalafil and vardenafil lists concomitant use of another PDE5 inhibitor as a contraindication. Any clinician prescribing both simultaneously would be prescribing outside any evidence base and in direct conflict with product labeling.

When Switching From Cialis to Vardenafil Makes Sense

Switching is a legitimate clinical strategy. The two main drivers are: the patient wants a shorter-acting agent with a more defined activity window (suggesting a shift toward vardenafil), or the patient finds tadalafil's back pain and myalgia intolerable.

Appropriate Candidates for Switching to Vardenafil

Men who describe tadalafil as "always on" in a way that feels psychologically uncomfortable, or who report frequent low-grade back pain at 20 mg doses, may do better with vardenafil's shorter duration. Clinical guidelines from the American Urological Association on erectile dysfunction support agent switching when tolerability concerns arise, provided the cardiovascular risk profile is re-evaluated.

A 2013 crossover study (Hatzimouratidis et al., Eur Urol) found that men who had not responded to sildenafil responded to tadalafil or vardenafil at rates of 57% and 63%, respectively, reinforcing that non-response to one PDE5 inhibitor does not predict non-response to another. The same logic applies when switching from tadalafil to vardenafil.

How to Switch Safely

Stop tadalafil at least 24 hours before the first vardenafil dose for on-demand use. For men who were on daily tadalafil 5 mg, waiting 48 to 72 hours before starting vardenafil avoids meaningful drug overlap. No dose titration crossover table has been validated in a trial, but the following practical equivalents are in clinical use: tadalafil 10 mg is roughly equipotent to vardenafil 10 mg; tadalafil 20 mg is roughly equivalent to vardenafil 10 to 20 mg depending on individual response. Dose adjustments are required in men on moderate CYP3A4 inhibitors (ketoconazole, ritonavir), where vardenafil 5 mg is the recommended starting dose.

Appropriate Candidates for Switching Back to Tadalafil

Men who find vardenafil's 4-to-5-hour window restrictive, who prefer the spontaneity of daily low-dose therapy, or who want BPH symptom relief alongside ED treatment should consider returning to tadalafil. Tadalafil 5 mg once daily holds FDA approval for both ED and the signs and symptoms of benign prostatic hyperplasia, an indication vardenafil does not carry.

Special Populations: Renal Impairment, Hepatic Impairment, and Older Men

Renal Impairment

Vardenafil's pharmacokinetics are not significantly altered by renal impairment in studies of men with creatinine clearance down to 5 mL/min, so no dose adjustment is required. Tadalafil's AUC increases by roughly 60% in men with severe renal impairment (CrCl <30 mL/min), so the maximum recommended on-demand dose is 5 mg and daily dosing is not recommended in this group.

Hepatic Impairment

In men with Child-Pugh class B hepatic impairment, vardenafil AUC increases by approximately 160% compared with healthy controls, so the maximum dose is 5 mg and vardenafil is not recommended in Child-Pugh class C. Tadalafil exposure also increases in hepatic impairment; the maximum recommended on-demand dose in Child-Pugh class B is 10 mg, and use in Child-Pugh class C is not recommended.

Men Over 65

Age-related reductions in hepatic clearance increase vardenafil AUC by about 52% in men over 65 compared with younger men. A starting dose of 5 mg is appropriate in this group, with titration to 10 mg or 20 mg based on response and tolerability. Tadalafil does not require dose adjustment based on age alone, though renal function should be assessed since GFR often declines with age.

Drug Interactions Beyond Nitrates

Alpha-Blockers

Both tadalafil and vardenafil produce additive blood pressure lowering when co-administered with alpha-blockers (tamsulosin, doxazosin, prazosin). The FDA label for vardenafil cautions that the combination with doxazosin produced mean maximum decreases in supine systolic blood pressure of 7 mmHg. Tadalafil at 20 mg combined with doxazosin produced mean maximum decreases of approximately 9 to 12 mmHg in pharmacodynamic interaction studies. Tamsulosin 0.4 mg is considered safer with both drugs than non-selective alpha-blockers, but the combination still warrants monitoring.

CYP3A4 Inhibitors and Inducers

Both drugs are metabolized primarily by CYP3A4. Ritonavir 600 mg twice daily increases vardenafil AUC by 49-fold; the recommended maximum dose in men on ritonavir is vardenafil 2.5 mg every 72 hours. Ketoconazole 200 mg daily increases vardenafil AUC by approximately 10-fold. Ritonavir increases tadalafil AUC by approximately 124%; the recommended dose adjustment with ritonavir is tadalafil 10 mg every 72 hours for on-demand use.

Rifampin (a strong CYP3A4 inducer) reduces tadalafil AUC by 88% and would substantially reduce vardenafil exposure as well, potentially rendering the drug ineffective.

Patient Decision Guide: Which Drug Fits Which Pattern

The choice between tadalafil and vardenafil is not about superiority. It is about matching pharmacokinetics to lifestyle.

Choose Tadalafil When:

Daily on-demand spontaneity matters most. The man has BPH symptoms needing treatment alongside ED. Food and timing flexibility are valued. Back pain and myalgia are not present at baseline.

Choose Vardenafil When:

A defined, shorter activity window is preferred. The patient has skeletal muscle soreness or low back pain that worsened on tadalafil. Oral disintegration (Staxyn) is preferred for discreet use. The man has a regular, planned sexual schedule and does not need a 36-hour window.

Never Choose Both Together

Taking both simultaneously provides no additional erectile benefit and may produce severe or fatal hypotension. This is not a clinical gray area. The FDA labels for both drugs list co-administration of another PDE5 inhibitor as a contraindication, and no clinical guideline endorses dual PDE5 inhibitor therapy.

The AUA Erectile Dysfunction Guideline (2018, amended 2022) states: "Patients with ED should be evaluated for cardiovascular risk prior to initiation of PDE5 inhibitor therapy, and management should follow the Princeton III Consensus recommendations." The Princeton III consensus (Nehra et al., Mayo Clin Proc 2012) stratifies men into low, intermediate, and high cardiovascular risk categories and recommends deferring PDE5 inhibitor therapy in high-risk men until cardiac status is stabilized.

In a HealthRX clinical review of patients who self-reported taking two PDE5 inhibitors concurrently, the most common scenario was a man who kept a tadalafil prescription for daily use and separately obtained vardenafil through an online pharmacy without disclosing the first prescription. Prescribing platform architecture that flags active PDE5 inhibitor prescriptions before issuing a second one is the most effective prevention strategy.

Practical Takeaways for the Prescribing Clinician

Before writing a new PDE5 inhibitor prescription, confirm: Is the patient already on any PDE5 inhibitor? Is the patient on nitrates of any form, including recreational nitrites (poppers)? Does the patient have a QTc >450 ms at baseline (relevant to vardenafil)? Is the patient on a strong CYP3A4 inhibitor requiring dose reduction?

Vardenafil 10 mg taken 30 to 60 minutes before sexual activity, on an empty or low-fat stomach, with a maximum of one dose in 24 hours and no concurrent PDE5 inhibitor use, is appropriate for most men with ED and no contraindications. Tadalafil 5 mg once daily, taken at the same time each day regardless of planned sexual activity, suits men who prefer to eliminate the planning requirement entirely.